Review of commercially available biomarkers in the diagnosis of prostate cancer
DOI:
https://doi.org/10.12775/JEHS.2022.12.11.025Keywords
Prostate cancer, PSA, Biomarkers, Urology, ProstateAbstract
Introduction
Diagnosing prostate cancer is a complex process. Although PSA testing remains the basic laboratory study, new biomarkers and test are evolving quickly.
Aim
The aim of this review was to summarize available tests and markers for diagnosing prostate cancer.
Materials and methods
Literature search was conducted using PubMed and Cohrane databases.
Results and conclusions
Detailed description of ExoDx, PCA3, SelectMDx, Mi-prostate Score, SChLAP1, PSA, PHI, 4K Score tests was presented. Available test ease qualification for a prostate biopsy or observation. Patients should be qualified individually in deciding on a specific test to be performed. Urologists should be aware of each test mechanism and limitations.
References
Becerra, M.F., V.S. Atluri, A.S. Bhattu, et al., Serum and urine biomarkers for detecting clinically significant prostate cancer. Urol Oncol, 2020.
Fujita, K. and N. Nonomura, Urinary biomarkers of prostate cancer. Int J Urol, 2018. 25(9): p. 770-779.
McKiernan, J., M.J. Donovan, V. O'Neill, et al., A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. JAMA Oncol, 2016. 2(7): p. 882-9.
McKiernan, J., M.J. Donovan, E. Margolis, et al., A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy. Eur Urol, 2018. 74(6): p. 731-738.
Tutrone, R., M.J. Donovan, P. Torkler, et al., Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2-10 ng/mL. Prostate Cancer Prostatic Dis, 2020.
Bussemakers, M.J., A. van Bokhoven, G.W. Verhaegh, et al., DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res, 1999. 59(23): p. 5975-9.
Neves, A.F., T.G. Araujo, W.K. Biase, et al., Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis. Clin Biochem, 2008. 41(14-15): p. 1191-8.
Loeb, S., Does PCA3 help identify clinically significant prostate cancer? Eur Urol, 2008. 54(5): p. 980-1.
Deras, I.L., S.M. Aubin, A. Blase, et al., PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol, 2008. 179(4): p. 1587-92.
Whitman, E.J., J. Groskopf, A. Ali, et al., PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol, 2008. 180(5): p. 1975-8; discussion 1978-9.
Nakanishi, H., J. Groskopf, H.A. Fritsche, et al., PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol, 2008. 179(5): p. 1804-9; discussion 1809-10.
Qin, Z., J. Yao, L. Xu, et al., Diagnosis accuracy of PCA3 level in patients with prostate cancer: a systematic review with meta-analysis. Int Braz J Urol, 2019. 45.
Van Neste, L., R.J. Hendriks, S. Dijkstra, et al., Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. Eur Urol, 2016. 70(5): p. 740-748.
Raja, N., C.M. Russell, and A.K. George, Urinary markers aiding in the detection and risk stratification of prostate cancer. Transl Androl Urol, 2018. 7(Suppl 4): p. S436-S442.
Esgueva, R., S. Perner, J.L. C, et al., Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol, 2010. 23(4): p. 539-46.
Hagglof, C., P. Hammarsten, K. Stromvall, et al., TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers. PLoS One, 2014. 9(2): p. e86824.
Fradet, Y., F. Saad, A. Aprikian, et al., uPM3, a new molecular urine test for the detection of prostate cancer. Urology, 2004. 64(2): p. 311-5; discussion 315-6.
Wei, J.T., Z. Feng, A.W. Partin, et al., Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol, 2014. 32(36): p. 4066-72.
Tomlins, S.A., J.R. Day, R.J. Lonigro, et al., Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol, 2016. 70(1): p. 45-53.
Prensner, J.R., M.K. Iyer, A. Sahu, et al., The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet, 2013. 45(11): p. 1392-8.
Lin, D., Commentary on "RNA biomarkers associated with metastatic progression in prostate cancer: A multi-institutional high-throughput analysis of SChLAP1." Prensner JR, Zhao S, Erho N, Schipper M, Iyer MK, Dhanasekaran SM, Magi-Galluzzi C, Mehra R, Sahu A, Siddiqui J, Davicioni E, Den RB, Dicker AP, Karnes RJ, Wei JT, Klein EA, Jenkins RB, Chinnaiyan AM, Feng FY, University of Washington-Urology, Seattle, WA. Lancet Oncol 2014; 15(13):1469-80. Urol Oncol, 2016. 34(11): p. 521-522.
Catalona, W.J., D.S. Smith, and D.K. Ornstein, Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA, 1997. 277(18): p. 1452-5.
Catalona, W.J., A.W. Partin, M.G. Sanda, et al., A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol, 2011. 185(5): p. 1650-5.
Punnen, S., N. Pavan, and D.J. Parekh, Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer. Rev Urol, 2015. 17(1): p. 3-13.
Zappala, S.M., P.T. Scardino, D. Okrongly, et al., Clinical performance of the 4Kscore Test to predict high-grade prostate cancer at biopsy: A meta-analysis of us and European clinical validation study results. Rev Urol, 2017. 19(3): p. 149-155.
Stattin, P., A.J. Vickers, D.D. Sjoberg, et al., Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study. Eur Urol, 2015. 68(2): p. 207-13.
El-Shater Bosaily, A., C. Parker, L.C. Brown, et al., PROMIS--Prostate MR imaging study: A paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer. Contemp Clin Trials, 2015. 42: p. 26-40.
Ahmed, H.U., A. El-Shater Bosaily, L.C. Brown, et al., Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet, 2017. 389(10071): p. 815-822.
Fasulo, V. Clinical utility of biomarkers 4K score, SelectMDx and ExoDx with MRI for the detection of high-grade prostate cancer. 2020; Available from: https://www.exosomedx.com/sites/default/files/2020-02/Meeting%20Library%20_%20Clinical%20utility%20of%20biomarkers%204K%20score%2C%20SelectMDx%20and%20ExoDx%20with%20MRI%20for%20the%20detection%20of%20high-grade%20prostate%20cancer_.pdf.
Osses, D.F., M.J. Roobol, and I.G. Schoots, Prediction Medicine: Biomarkers, Risk Calculators and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer Diagnosis. Int J Mol Sci, 2019. 20(7).
Sathianathen, N.J., K.M. Kuntz, F. Alarid-Escudero, et al., Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis. J Urol, 2018. 200(6): p. 1215-1220.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Magdalena Ostrowska, Iwona Handzlik, Martyna Radomska, Adam Ostrowski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 559
Number of citations: 0
